Possible transfusion transmitted cerebral amyloid angiopathy: evaluation of transmission of Aβ using the RADAR repository

PROJECT SUMMARY/ABSTRACT Cerebral amyloid angiopathy (CAA) is a common cause of spontaneous intracerebral hemorrhage (ICH), with a case fatality rate of 30-50%. CAA is characterized by aggregation of likely misfolded deposits of amyloid β (Aβ) in the cerebral vasculature, leading to vascular weakening and repeated, unprovoked ICH. Over the past decade

evidence has been accumulating that Aβ exhibits prion-like properties, being overtly transmissible in experimental settings through a range of different parenteral routes. More pressingly, still, parenteral iatrogenic Aβ transmissibility, leading to CAA development, has also been demonstrated in humans, following neurosurgery

and in patients treated with cadaveric human growth hormone. Given that prions are readily transfusion transmissible, this raises the disconcerting possibility that CAA and its related Aβ-associated conditions, are potentially transfusion transmissible. A large, bi-national, retrospective cohort study using the Swedish-Danish

SCANDAT transfusion database found that 0.1% of transfused patients in Sweden and Denmark received red- cell units from blood donors who later suffered repeated, unprovoked ICH, and that these patients were at a near-3-fold increased risk of themselves suffering an unprovoked ICH, as compared to patients who did not

receive red-cell units from affected blood donors. Under the hypothesis that the observed association was driven by Aβ transmission and CAA development in affected donors and recipients, the clinical implications could be very large, especially considering that Aβ aggregation is also strongly associated with Alzheimer’s disease.

However, external replication of these preliminary findings, ideally with biochemical and mechanistic corroboration, is urgently needed. We therefore propose to utilize the existing NHLBI REDS Allogeneic Donor and Recipient (RADAR) repository, with samples from both blood donors and pre- and post- transfusion samples

of transfused, to (a) investigate the prevalence of Amyloid β pathology through measures of the associated pTau217 protein among blood donors, and (b) investigate the possibility that amyloid β is transfusion- transmissible from affected donors to their transfused patients.